Advanced Practice Providers

Burnout

Concierge Medicine

Concierge Medicine 2.0 by Castle Connolly Private Health Partners

Employment Trends

Learning and Development

Locum Tenens, brought to you by LocumLife®

Maintenance of Certification

Careers

Contract Negotiation

Insurance

Malpractice

Risk Management

Legal

Data and Analytics

Device Pipeline and Approvals

Device Regulation and Policy

Earnings and Investment

Emerging Technology

Leaders and Innovators

Medtech Industry Trends

Mergers and Acquisitions

Point of Care

Tech Transfer

Medical Device & Technology

Opinion

Estate Planning

Investing

Retirement Planning

Physician's Money Digest

Industry Trends

Medicare & Medicaid

Pharma Industry

Physician Advocacy

Politics

Policy

Billing and Collections

Payment Models

Practice Valuation

Practice valuation

Reimbursement

Revenue Cycle Management

Practice Finance

Chronic Condition Management

Coding and Documentation

Leadership

Marketing

Patient Relations

Staffing

Vaccines

Practice Management

Cybersecurity

EHRs

Medical Technology

Remote Patient Monitoring

Telehealth

Practice Technology

Screening

100 Years of Medical Economics

Exclusive Content 

Special Reports

News

All News

Money

Physicians Financial News

Technology

Media

Around the Practice

Between The Lines

Clinical Consult

Expert Interviews

Medical Economics Pulse

Medical World News

Off The Charts Podcasts

Physician Report

PrimaryView

Slideshows

Academy

Conferences

Conference Coverage

Conference Listing

Publications

Medical Economics

Patient Care Supplement

Supplements And Featured Publications

CME/CE

Job Board

Subscribe

Directories

Financial Advisor Guide

Medical Economics serves as the connection to Physician Practice Management, featuring financial strategies, business insights, and expert interviews.

About

Advertise

Contact Us

Editorial Staff

Terms and Conditions

Contributor Guidelines

Privacy Policy

Do Not Sell My Personal Information

Medical Economics - Physician Business, Practice Management Coverage

Facebook

LinkedIn

Business Focus

Career Planning

Electronic Health Records

Personal Finance

Value-based Care

Locum Tenens

Clinical  Focus

Allergy and Immunology

Cardiology

Dermatology

Endocrinology

Gastroenterology

Infectious Disease

Neurology

Pain Management

Pediatrics

Psychiatry

Pulmonology

Rheumatology

Women's Health

Spotlight

The benefits of a physician MBA program

Physician Bootcamp

1rem

Topics

CEO Martin Burns discusses the origins of Bruin Biometrics and the Privizio SEM Scanner

The origins of Bruin Biometrics and the Privizio SEM Scanner

Back in 2012, Martin Burns spotted a UCLA-born device prototype in a magazine, a novel technology designed to detect pressure injuries, commonly known as bedsores, before they happen. Thirteen years later, the former strategy consultant and now Chief Executive Officer of 

 has spent the past decade turning the company and that technology into a global player in wound-care technology.

, Burns traces how that moment led to Bruin’s signature product: the Provizio SEM Scanner, a handheld device that uses capacitance to quantify sub-epidermal moisture and flag the risk of bedsores. The device can do this days before skin breaks down, regardless of a patient’s skin tone.

In this segment, Burns discusses the origins of the company, and the Provizio SEM Scanner.

Appointed CEO of Bruin Biometrics in 2012, Martin Burns designed and led the successful journey of Bruin Biometrics’ SEM Scanner through the company’s concept-to-commercialization “formulas strategy.” Significant milestones include FDA de novo Marketing Authorization (2018), CE Marking (2013) and in 2020 he negotiated a global distribution arrangement and investment with Arjo. Martins’ background is strategy and operations management consulting to large med tech companies. He earned his MBA from UCLA’s Anderson School of Management, where he is a guest speaker on healthcare strategy and medical device marketing courses, and his BA from the London School of Economics.

Videos

In a wide-ranging interview, Martin Burns discusses Bruin Biometrics’ Provizio SEM Scanner, why diagnostic and prevention tech innovation is underfunded and the challenges and opportunities facing the MedTech industry.

Martin Burns: The origins of Bruin Biometrics and the Provizio SEM Scanner

The origins of the Privizio SEM Scanner

From tech transfer to commercialization: The four formulas that guided Bruin Biometrics

How the Provizio SEM Scanner works

How the scanner improves patient-care protocols and nursing workflows

Challenges in the reimbursement landscape

What’s next for Bruin Biometrics

Challenges and opportunities facing the MedTech industry

The importance of diagnostic innovation

Burns explains the “formulas” strategy that guided the scanner from university lab bench to CE mark, FDA de novo clearance and more than 100 peer-reviewed studies, all aimed at one goal: eliminating preventable bedsores across every care setting.

He details how early detection reshapes nursing workflows, trims as much as seven hours of staff time per ward each day and delivers the rare combination of better outcomes at lower cost. The conversation also tackles the tougher side of commercialization, securing breakthrough-device reimbursement pathways and making the scanner “free at the point of care.”

Looking ahead, Burns discusses PIPPA, an AI-powered bedside assistant designed to automate documentation and guide interventions and shares why he believes diagnostic innovation still lags on investors’ radar. The discussion closes with a candid assessment of med-tech headwinds — from tariff volatility to capital shortages — and why Burns remains bullish on artificial intelligence to propel the next wave of patient-safety advances.

Martin Burns of Bruin Biometrics: Leading the way on diagnostic innovation

Introducing the Rice Biotech Launch Pad

Why innovation is led by clinicians

Project Thor: A device to transform cancer treatment

Developing an implantable bioreactor

Balancing innovation and patient need

The benefits and challenges of tech transfer

The future of the Rice Biotech Launch Pad

 has set an ambitious course to transform lab discoveries into real-world solutions for patients, and at the center of this effort is 

, its faculty director and a professor of bioengineering at Rice University.

to offer his insights into how Rice University’s incubator fast-tracks promising biotech ventures — from cutting-edge immunotherapies to advanced diagnostic platforms — by pairing clinicians and researchers with entrepreneurs, investors and industry partners.

“Our projects all start with a clinician founder,” Veiseh said. “It’s a problem that a clinician has seen, either in treating their own patients or a trial they ran, that has a technological gap.”

Among the current slate of projects, teams are pushing the boundaries of cell therapy, regenerative medicine and medical device design. From developing new biomaterials that promote tissue healing to harnessing synthetic biology for next-generation cancer treatments, each project is laser-focused on bringing tangible benefits to physicians and patients, according to Veiseh.

The result is a growing pipeline of innovations poised to change the way physicians diagnose and treat complex diseases. Watch our conversation with Veiseh to learn more about the mission of the Rice biotech launch pad, details on some of its projects, trends in tech transfer, and how they manage the balance of targeting innovation that most benefits patients in need.

Veiseh is a professor and CPRIT Scholar in Cancer Research in the Departments of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He is also the Director of 

, a new initiative with a mission to accelerate the translation of Rice University's discoveries and technologies into clinical practice to provide rapid patient access to leading-edge therapeutic products. He leads an interdisciplinary translational research program to engineer and commercialize next-generation cell-based therapeutics for various human diseases. His team leverages the latest techniques in synthetic biology, immunoengineering, and material science to develop innovative cell-based platforms for real-time and feedback-regulated production of biologics. 

Throughout his career, he has authored or co-authored more than 80 peer-reviewed publications, including those in Nature Biotechnology, Nature Materials, Nature Medicine, and Nature Biomedical Engineering. He is an inventor on more than 50 pending or awarded patents. He is also a serial entrepreneur who has co-founded multiple biotechnology companies, collectively attracting ~ $500M in private and public investment capital. Dr. Veiseh has been elected as a fellow of the Controlled release Society and a member of the National Academy of Inventors.

Veiseh received a dual PhD in Materials Science & Engineering and Nanotechnology from the University of Washington. He completed his postdoctoral research with Prof. Robert Langer and Daniel G. Anderson at MIT and Harvard Medical School.

Omid Veiseh, PhD, faculty director of the Rice Biotech Launchpad, discusses his organization’s mission to create innovative biotechnology based on patient need.

Fostering clinician-led biotech innovation